Background and aims: We aimed to identify novel biomarkers for cardiovascular mortality through a non-targeted metabolomics approach in patients with established atherosclerotic disease from the Tor Vergata Atherosclerosis Registry (TVAR). Methods: We compared the serum baseline metabolome of 19 patients with atherosclerosis suffering from cardiovascular death during follow-up with the baseline serum metabolome of 20 control patients matched for age, gender, body mass index (BMI) and atherosclerotic disease status, who survived during the observation period. Results: Three metabolites were significantly different in the cardiovascular mortality (CVM) group compared to controls: 2-hydroxycaproate, gluconate and sorbitol. 2-hydroxycaproate (otherwise known as alpha hydroxy caproate) was also significantly correlated with time to death. The metabolites performed better when combined together rather than singularly on the identification of CVM status. Conclusions: Our analysis led to identify few metabolites potentially amenable of translation into the clinical practice as biomarkers for specific metabolic changes in the cardiovascular system in patients with established atherosclerotic disease.

Cardellini, M., Ballanti, M., Davato, F., Cardolini, I., Guglielmi, V., Rizza, S., et al. (2018). 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease. ATHEROSCLEROSIS, 277, 179-185 [10.1016/j.atherosclerosis.2018.06.014].

2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease

Cardellini, Marina;Ballanti, Marta;Davato, Francesca;Guglielmi, Valeria;Rizza, Stefano;Pecchioli, Chiara;Casagrande, Viviana;Mavilio, Maria;Porzio, Ottavia;Legramante, Jacopo M.;Ippoliti, Arnaldo;Farcomeni, Alessio;Sbraccia, Paolo;Menghini, Rossella;Kappel, Ben A.;Federici, Massimo
2018-01-01

Abstract

Background and aims: We aimed to identify novel biomarkers for cardiovascular mortality through a non-targeted metabolomics approach in patients with established atherosclerotic disease from the Tor Vergata Atherosclerosis Registry (TVAR). Methods: We compared the serum baseline metabolome of 19 patients with atherosclerosis suffering from cardiovascular death during follow-up with the baseline serum metabolome of 20 control patients matched for age, gender, body mass index (BMI) and atherosclerotic disease status, who survived during the observation period. Results: Three metabolites were significantly different in the cardiovascular mortality (CVM) group compared to controls: 2-hydroxycaproate, gluconate and sorbitol. 2-hydroxycaproate (otherwise known as alpha hydroxy caproate) was also significantly correlated with time to death. The metabolites performed better when combined together rather than singularly on the identification of CVM status. Conclusions: Our analysis led to identify few metabolites potentially amenable of translation into the clinical practice as biomarkers for specific metabolic changes in the cardiovascular system in patients with established atherosclerotic disease.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
Settore MED/13 - Endocrinologia
Settore MED/09 - Medicina Interna
Settore SECS-S/01 - Statistica
English
Con Impact Factor ISI
2-hydroxycaproate; Atherosclerosis; Biomarker; Cardiovascular mortality; Metabolomics; Cardiology and Cardiovascular Medicine
www.elsevier.com/locate/atherosclerosis
Cardellini, M., Ballanti, M., Davato, F., Cardolini, I., Guglielmi, V., Rizza, S., et al. (2018). 2-hydroxycaproate predicts cardiovascular mortality in patients with atherosclerotic disease. ATHEROSCLEROSIS, 277, 179-185 [10.1016/j.atherosclerosis.2018.06.014].
Cardellini, M; Ballanti, M; Davato, F; Cardolini, I; Guglielmi, V; Rizza, S; Pecchioli, C; Casagrande, V; Mavilio, M; Porzio, O; Legramante, Jm; Ippoliti, A; Farcomeni, A; Sbraccia, P; Menghini, R; Dumas, Me; Kappel, Ba; Federici, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0021915018303265-main.pdf

accesso aperto

Licenza: Copyright dell'editore
Dimensione 1.15 MB
Formato Adobe PDF
1.15 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/210478
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact